Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80522
Name thyroid gland anaplastic carcinoma
Definition A thyroid gland carcinoma that is composed of undifferentiated cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland anaplastic carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib + Trametinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E Vemurafenib thyroid gland anaplastic carcinoma predicted - sensitive detail...
RET fusion Selpercatinib thyroid gland anaplastic carcinoma sensitive detail...
RET fusion Pralsetinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E PIK3CA M1043I Dasatinib + Trametinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E PIK3CA H1047R Dasatinib + Trametinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E PIK3CA N1044S Dasatinib + Trametinib thyroid gland anaplastic carcinoma resistant detail...
BRAF V600E PIK3CA E542K Dasatinib + Trametinib thyroid gland anaplastic carcinoma resistant detail...
BRAF V600E PIK3CA E542K GSK2334470 + Trametinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E PIK3CA N1044S GSK2334470 + Trametinib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E PIK3CA N1044S Dasatinib + MK2206 + Trametinib thyroid gland anaplastic carcinoma resistant detail...
BRAF V600E PIK3CA E542K Dasatinib + MK2206 + Trametinib thyroid gland anaplastic carcinoma resistant detail...
BRAF V600E Binimetinib + Encorafenib thyroid gland anaplastic carcinoma sensitive detail...
BRAF V600E Ravoxertinib thyroid gland anaplastic carcinoma sensitive detail...
NRAS Q61K Ravoxertinib thyroid gland anaplastic carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Active, not recruiting USA 0
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Recruiting USA | GBR 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | ESP 1
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Active, not recruiting ESP 0
NCT04238624 Phase II Cemiplimab + Dabrafenib + Trametinib Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Active, not recruiting ESP 0
NCT04420754 Phase I AIC100 Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04552769 Phase II Abemaciclib Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Active, not recruiting USA 0
NCT04675710 Phase II Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer Recruiting USA 0
NCT04759911 Phase II Selpercatinib Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Recruiting USA 0
NCT05059470 Phase II Pembrolizumab IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC Recruiting USA 0
NCT05119296 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Recruiting USA 0
NCT05453799 Phase II XmAb20717 Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer Recruiting USA 0
NCT05668585 Phase Ib/II CFT1946 + Trametinib CFT1946 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Recruiting USA | FRA | ESP 0
NCT06007924 Phase II Defactinib + RO5126766 A Study of Avutometinib and Defactinib in People With Thyroid Cancer Recruiting USA 0
NCT06079333 Phase II Dabrafenib + Trametinib NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT) Recruiting NLD 0
NCT06235216 Phase II Sacituzumab govitecan-hziy Sacituzumab govitEcan in THYroid Cancers (SETHY) Not yet recruiting ESP 0